Compositions Comprising Ephedrine or an Ephedrine Salt and Methods of Making and Using Same
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 62/849,125, filed May 16, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,090,278 | Compositions Comprising Ephedrine or an Ephedrine Salt and Methods of Making and Using Same In force · High confidence | Nexus Pharmaceuticals, LLC | In force | High confidence | ||
| US 11,241,400 | Compositions Comprising Ephedrine or an Ephedrine Salt and Methods of Making and Using Same In force · High confidence | Nexus Pharmaceuticals, LLC | In force | High confidence | ||
| US 11,426,369 | Compositions Comprising Ephedrine or an Ephedrine Salt and Methods of Making and Using Same In force · Medium confidence | Nexus Pharmaceuticals, LLC | In force | Medium confidence | ||
| US 11,464,752 | Compositions Comprising Ephedrine or an Ephedrine Salt and Methods of Making and Using Same In force · High confidence | Nexus Pharmaceuticals, LLC | In force | High confidence | ||
| US 11,478,436 | Compositions Comprising Ephedrine or an Ephedrine Salt and Methods of Making and Using Same In force · Medium confidence | Nexus Pharmaceuticals, LLC | In force | Medium confidence | ||
| US 11,571,398 | Compositions Comprising Ephedrine or an Ephedrine Salt and Methods of Making and Using Same In force · Medium confidence | Nexus Pharmaceuticals, LLC | In force | Medium confidence | ||
| US 12,797,345 | Compositions Comprising Ephedrine or an Ephedrine Salt and Methods of Making and Using Same In force · Medium confidence | Nexus Pharmaceuticals, LLC | In force | Medium confidence |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.